EA202091974A1 - Связывающие bcma антитела и их применение - Google Patents
Связывающие bcma антитела и их применениеInfo
- Publication number
- EA202091974A1 EA202091974A1 EA202091974A EA202091974A EA202091974A1 EA 202091974 A1 EA202091974 A1 EA 202091974A1 EA 202091974 A EA202091974 A EA 202091974A EA 202091974 A EA202091974 A EA 202091974A EA 202091974 A1 EA202091974 A1 EA 202091974A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bcma
- antibodies
- patient
- binders
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Предложены антитела, которые связывают антиген созревания В-клеток (BCMA), а также способы истощения экспрессирующих BCMA клеток у пациента, нуждающегося в этом, включающие в себя введение терапевтически эффективного количества антител или объекта, содержащего их BCMA-связывающий фрагмент. Предложены способы лечения связанных с В-клетками заболеваний, ассоциированных с экспрессией BCMA, у пациента, нуждающегося в этом, включающие в себя введение пациенту терапевтически эффективного количества антител или объекта, содержащего их BCMA-связывающий фрагмент.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633152P | 2018-02-21 | 2018-02-21 | |
PCT/US2019/018698 WO2019164891A1 (en) | 2018-02-21 | 2019-02-20 | Bcma-binding antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091974A1 true EA202091974A1 (ru) | 2020-12-08 |
Family
ID=65686040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091974A EA202091974A1 (ru) | 2018-02-21 | 2019-02-20 | Связывающие bcma антитела и их применение |
Country Status (15)
Country | Link |
---|---|
US (2) | US11401336B2 (ru) |
EP (1) | EP3755718A1 (ru) |
JP (1) | JP2021514193A (ru) |
KR (1) | KR20200123155A (ru) |
CN (1) | CN112272675A (ru) |
AR (1) | AR115257A1 (ru) |
AU (1) | AU2019223076A1 (ru) |
BR (1) | BR112020017053A2 (ru) |
CA (1) | CA3092037A1 (ru) |
EA (1) | EA202091974A1 (ru) |
IL (1) | IL276548A (ru) |
MX (1) | MX2020008718A (ru) |
SG (1) | SG11202007495SA (ru) |
TW (1) | TW202000701A (ru) |
WO (1) | WO2019164891A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20220221A (es) * | 2019-11-18 | 2022-07-11 | Janssen Biotech Inc | Receptores del antígeno quimérico anti-cd79, células car-t, y uoso de estos |
US20230172923A1 (en) * | 2020-04-30 | 2023-06-08 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
JP2023542257A (ja) | 2020-09-16 | 2023-10-05 | アムジェン インコーポレイテッド | 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法 |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5998656A (en) | 1991-09-23 | 1999-12-07 | Florida State University | C10 tricyclic taxanes |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5703247A (en) | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5763477A (en) | 1994-07-22 | 1998-06-09 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III |
WO1996028435A1 (en) | 1995-03-10 | 1996-09-19 | Hauser Chemical Research, Inc. | Cephalomannine epoxide, its analogues and a method for preparing the same |
DK0925294T6 (da) | 1996-07-24 | 2018-08-20 | Celgene Corp | Substituerede 2-(2,6-dioxopiperidin-3-yl)phthalimider og -1-oxoisoindoliner samt fremgangsmåde til reduktion af tnf-alpha-niveauer |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
ATE236872T1 (de) | 1996-08-12 | 2003-04-15 | Celgene Corp | Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
KR100712573B1 (ko) | 1998-03-16 | 2007-05-02 | 셀진 코포레이션 | 염증성 사이토카인 억제제용 2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그 제조방법 및 그 용도 |
HUP0200499A3 (en) | 1999-03-18 | 2002-12-28 | Celgene Corp Warren | Substituted 1-oxo- and 1,3-dioxoisoindolines and their use for preparation of pharmaceutical compositions for reducing inflammatory cytokine levels |
NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
MX2007006439A (es) | 2004-12-01 | 2007-07-20 | Celgene Corp | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento de trastornos de inmunodeficiencia. |
ZA200707010B (en) | 2005-01-25 | 2009-01-28 | Celgene Corp | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidini-3-yl)-isoindole-1-3-dione |
UA91560C2 (ru) | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
ME02420B (me) | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
US8207306B2 (en) * | 2008-09-19 | 2012-06-26 | Medimmune, Llc | Targeted binding agents directed to sonic hedgehog homolog and uses thereof |
UA114856C2 (uk) | 2010-02-11 | 2017-08-10 | Селджин Корпорейшн | Способи лікування із застосуванням похідних арилметоксіізоіндоліну |
PL2683708T3 (pl) | 2011-03-11 | 2018-03-30 | Celgene Corporation | Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania |
EP3415531B1 (en) * | 2011-05-27 | 2023-09-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - binding proteins |
MX358517B (es) | 2012-06-29 | 2018-08-24 | Celgene Corp | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
SG11201608415QA (en) * | 2014-04-30 | 2016-11-29 | Max Delbrück Ct Für Molekulare Medizin In Der Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-bcma嵌合抗原受體治療癌症 |
EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
LT3230321T (lt) * | 2014-12-12 | 2019-12-10 | Bluebird Bio Inc | Bcma chimeriniai antigeno receptoriai |
US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
EP3757128A1 (en) * | 2015-04-13 | 2020-12-30 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
CA2925329C (en) * | 2015-04-13 | 2024-01-02 | Pfizer Inc. | Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3 |
EA036975B1 (ru) | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
JP6901493B2 (ja) * | 2015-11-13 | 2021-07-14 | アメリカ合衆国 | 抗bcmaポリペプチド及びタンパク質 |
NZ746700A (en) * | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
-
2019
- 2019-02-20 SG SG11202007495SA patent/SG11202007495SA/en unknown
- 2019-02-20 CA CA3092037A patent/CA3092037A1/en active Pending
- 2019-02-20 KR KR1020207026078A patent/KR20200123155A/ko not_active Application Discontinuation
- 2019-02-20 WO PCT/US2019/018698 patent/WO2019164891A1/en unknown
- 2019-02-20 JP JP2020544223A patent/JP2021514193A/ja active Pending
- 2019-02-20 AU AU2019223076A patent/AU2019223076A1/en active Pending
- 2019-02-20 EP EP19709253.9A patent/EP3755718A1/en not_active Withdrawn
- 2019-02-20 MX MX2020008718A patent/MX2020008718A/es unknown
- 2019-02-20 BR BR112020017053-4A patent/BR112020017053A2/pt unknown
- 2019-02-20 EA EA202091974A patent/EA202091974A1/ru unknown
- 2019-02-20 US US16/971,925 patent/US11401336B2/en active Active
- 2019-02-20 CN CN201980027397.4A patent/CN112272675A/zh active Pending
- 2019-02-21 TW TW108105895A patent/TW202000701A/zh unknown
- 2019-02-22 AR ARP190100439A patent/AR115257A1/es unknown
-
2020
- 2020-08-06 IL IL276548A patent/IL276548A/en unknown
-
2022
- 2022-06-17 US US17/807,473 patent/US20220324991A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200399386A1 (en) | 2020-12-24 |
WO2019164891A9 (en) | 2020-09-17 |
US20220324991A1 (en) | 2022-10-13 |
CN112272675A (zh) | 2021-01-26 |
EP3755718A1 (en) | 2020-12-30 |
SG11202007495SA (en) | 2020-09-29 |
CA3092037A1 (en) | 2019-08-29 |
US11401336B2 (en) | 2022-08-02 |
JP2021514193A (ja) | 2021-06-10 |
WO2019164891A1 (en) | 2019-08-29 |
KR20200123155A (ko) | 2020-10-28 |
AU2019223076A1 (en) | 2020-10-08 |
BR112020017053A2 (pt) | 2020-12-15 |
AR115257A1 (es) | 2020-12-16 |
IL276548A (en) | 2020-09-30 |
MX2020008718A (es) | 2020-12-07 |
TW202000701A (zh) | 2020-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
EA202090739A1 (ru) | Белки, связывающие антиген созревания в-клеток | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
EA202091977A1 (ru) | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения | |
EA201790530A1 (ru) | Агенты, связывающиеся с cd123, и виды их применения | |
MX2020008336A (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. | |
EA202190773A1 (ru) | CD1d ИММУНОГЛОБУЛИН ДВОЙНОГО ДЕЙСТВИЯ | |
EA202092668A1 (ru) | Антитела к ил-11 | |
EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
WO2015112805A8 (en) | Human antibodies to pd-l1 | |
EA202091976A1 (ru) | Вариабельные домены антител, нацеленные на cd33, и их применение | |
EA201892774A1 (ru) | Антитела | |
AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
EA201491452A1 (ru) | Антитела к asic1 и их применение | |
EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
EA201591762A1 (ru) | Человеческие антитела к grem1 | |
EA202190468A1 (ru) | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения | |
BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
EA202190573A1 (ru) | Композиции и способы перепрограммирования tcr с применением гибридных белков |